Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally.
Adequate balance sheet with limited growth.
Share Price & News
How has Invitae's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IV8's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IV8 exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: IV8 exceeded the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Invitae's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Invitae undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IV8's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IV8's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IV8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IV8 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IV8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IV8 is overvalued based on its PB Ratio (6.5x) compared to the DE Biotechs industry average (3.5x).
How is Invitae forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IV8 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IV8 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IV8 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IV8's revenue (30.1% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: IV8's revenue (30.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IV8 is forecast to be unprofitable in 3 years.
How has Invitae performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IV8 is currently unprofitable.
Growing Profit Margin: IV8 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IV8 is unprofitable, and losses have increased over the past 5 years at a rate of -20.9% per year.
Accelerating Growth: Unable to compare IV8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IV8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: IV8 has a negative Return on Equity (-48.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Invitae's financial position?
Financial Position Analysis
Short Term Liabilities: IV8's short term assets ($508.5M) exceed its short term liabilities ($68.9M).
Long Term Liabilities: IV8's short term assets ($508.5M) exceed its long term liabilities ($317.6M).
Debt to Equity History and Analysis
Debt Level: IV8's debt to equity ratio (65.7%) is considered high.
Reducing Debt: IV8's debt to equity ratio has increased from 0% to 65.7% over the past 5 years.
Inventory Level: IV8 has a low level of unsold assets or inventory.
Debt Coverage by Assets: IV8's debt is covered by short term assets (assets are 1.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IV8 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IV8 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -17.6% each year
What is Invitae's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IV8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IV8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IV8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IV8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IV8's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sean George (45yo)
Dr. Sean E. George, Ph.D. is the Co-Founder of InVitae Corporation and has been its President since August 2012. Dr. George has been Chief Executive Officer of InVitae Corporation since January 9, 2017 and ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD2.23M) is about average for companies of similar size in the German market ($USD2.02M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
|Secretary & COO||2.7yrs||US$1.48m||0.036% $873.3k|
|Chief Commercial Officer||3.3yrs||US$1.48m||0.024% $575.0k|
|Chief Financial Officer||2.7yrs||US$1.40m||0.025% $612.6k|
|General Counsel||3.1yrs||no data||0.035% $831.3k|
|Chief Medical Officer||4.5yrs||US$802.74k||0.15% $3.6m|
Experienced Management: IV8's management team is considered experienced (3.1 years average tenure).
|Independent Director||9.4yrs||US$96.27k||no data|
|Independent Director||4.3yrs||US$91.27k||no data|
|Independent Director||7.9yrs||US$96.27k||0.030% $730.2k|
|Independent Director||1.4yrs||US$164.89k||no data|
Experienced Board: IV8's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.9%.
Invitae Corporation's company bio, employee growth, exchange listings and data sources
- Name: Invitae Corporation
- Ticker: IV8
- Exchange: DB
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.610b
- Listing Market Cap: US$2.409b
- Shares outstanding: 96.52m
- Website: https://www.invitae.com
Number of Employees
- Invitae Corporation
- 1400 16th Street
- San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVTA||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Feb 2015|
|IV8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2015|
|0JDB||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 2015|
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:29|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.